Table 1 Baseline demographics and characteristics of the included AGHD patients
Measurement | Female control group | Female treated group | Male control group | Male treated group | ||||
|---|---|---|---|---|---|---|---|---|
N | Mean ± SD | N | Mean ± SD | N | Mean ± SD | N | Mean ± SD | |
Age (years) | 9 | 51.60 ± 16.76 | 31 | 44.86 ± 13.05 | 13 | 57.16 ± 12.88 | 53 | 48.73 ± 14.69 |
GH starting dose (mg/day) | 9 | 0.00 ± 0.00 | 31 | 0.23 ± 0.13 | 13 | 0.00 ± 0.00 | 53 | 0.20 ± 0.09 |
IGF-I SDS | 9 | −1.13 ± 2.09 | 26 | −1.40 ± 1.44 | 12 | −1.58 ± 1.17 | 44 | −1.28 ± 1.72 |
Diagnosis at baseline | 9 | 31 | 13 | 53 | ||||
Acquired GHD (trauma) | 1 | 1 | 0 | 1 | ||||
Acquired GHD (pituitary tumour) | 4 | 9 | 7 | 25 | ||||
Acquired GHD (surgery/irradiation) | 1 | 14 | 5 | 10 | ||||
Acquired GHD (other) | 2 | 4 | 0 | 6 | ||||
Idiopathic GHD | 1 | 0 | 0 | 5 | ||||
Hypopituitarism/pituitary abnormality | 0 | 3 | 1 | 5 | ||||
Craniopharyngioma | 0 | 0 | 0 | 1 | ||||